{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:16:22Z","timestamp":1792696582738,"version":"4.5.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      The diminishing efficacy of conventional antibiotics against methicillin-resistant\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      (MRSA) necessitates novel therapeutic strategies. Drug repurposing represents a promising approach. This study investigates the antibacterial potential of Nifuratel, a repurposed agent, against MRSA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      <jats:italic>In vitro<\/jats:italic>\n                      antibacterial activity was assessed against type strains and clinical isolates via minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) assays. The propensity for resistance development was evaluated. Sub-MIC effects on key virulence phenotypes-biofilm formation, hemolysis, auto-aggregation, and surface spreading-were examined. The mechanism of action was investigated using transmission electron microscopy, fluorescence probes, and molecular dynamics simulations. Efficacy and biocompatibility were evaluated\n                      <jats:italic>in vivo<\/jats:italic>\n                      using murine abscess and wound infection models, with assessments of bacterial load, inflammation, wound healing, hemolysis, and organ toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nifuratel exhibited potent bactericidal activity with MICs of 2\u20138 \u00b5g\/mL and MBCs of 8\u201316 \u00b5g\/mL, and a low propensity for resistance development. At sub-MIC concentrations, it significantly suppressed MRSA virulence phenotypes. Mechanistic studies revealed that Nifuratel disrupts the proton motive force by dissipating both the transmembrane potential and proton gradient, without causing direct membrane damage.\n                      <jats:italic>In vivo<\/jats:italic>\n                      , Nifuratel treatment significantly reduced bacterial loads, attenuated inflammation, and promoted wound healing comparably to fusidic acid. The compound demonstrated excellent biocompatibility with minimal hemolysis and no observed organ toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      These results identify Nifuratel as a promising repurposed antimicrobial agent against MRSA. Its dual capability to exert direct bactericidal activity by disrupting PMF and attenuate key virulence factors, combined with a favorable resistance profile and biocompatibility\n                      <jats:italic>in vivo<\/jats:italic>\n                      , supports its potential for further therapeutic development.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2025.1738031","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:42:15Z","timestamp":1767940935000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug repurposing of Nifuratel against methicillin-resistant Staphylococcus aureus through proton motive force disruption"],"prefix":"10.3389","volume":"15","author":[{"given":"Pengfei","family":"She","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kening","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"B42","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5414\/CN109651","article-title":"Telavancin-associated acute kidney injury","volume":"91","author":"Cavanaugh","year":"2019","journal-title":"Clin. Nephrol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1093\/jac\/dky365","article-title":"Efficacy of chimeric ectolysin P128 in drug-resistant Staphylococcus aureus bacteraemia in mice","volume":"73","author":"Channabasappa","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e01358","DOI":"10.1128\/AAC.01358-17","article-title":"Efficacy of novel antistaphylococcal ectolysin P128 in a rat model of Methicillin-resistant Staphylococcus aureus bacteremia","volume":"62","author":"Channabasappa","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02056-22","article-title":"Dioxane-linked novel bacterial topoisomerase inhibitors exhibit bactericidal activity against planktonic and biofilm Staphylococcus aureus in vitro","volume":"10","author":"Chen","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"B20","volume-title":"M100 performance standards for antimicrobial susceptibility testing","year":"2024"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1128\/AAC.01888-13","article-title":"Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus isolates and vancomycin-intermediate S","volume":"58","author":"Dilworth","year":"2014","journal-title":"aureus isolates vitro. Antimicrob. Agents Chemother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/nchembio.559","article-title":"Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy","volume":"7","author":"Ejim","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.chembiol.2013.07.006","article-title":"Collapsing the proton motive force to identify synergistic combinations against Staphylococcus aureus","volume":"20","author":"Farha","year":"2013","journal-title":"Chem. Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e01846","DOI":"10.1128\/AAC.01846-16","article-title":"Repurposing toremifene for treatment of oral bacterial infections","volume":"61","author":"Gerits","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1136\/bmj.2.6041.908","article-title":"Treatment of candidal urinary tract infection with nifuratel","volume":"2","author":"Gruneberg","year":"1976","journal-title":"Br. Med. J."},{"key":"B43","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/BF01975036","article-title":"Antibiotic uptake into gram-negative bacteria","volume":"7","author":"Hancock","year":"1988","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/microbiolspec.GPP3-0031-2018","article-title":"Regulation of Staphylococcus aureus virulence","volume":"7","author":"Jenul","year":"2019","journal-title":"Microbiol. Spectr."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1021\/acscentsci.3c00499","article-title":"Repurposed fenoprofen targeting SaeR attenuates Staphylococcus aureus virulence in implant-associated infections","volume":"9","author":"Jiang","year":"2023","journal-title":"ACS Cent Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"104289","DOI":"10.1016\/j.phrs.2019.104289","article-title":"Non-antibiotic adjunctive therapy: A promising approach to fight tuberculosis","volume":"146","author":"Khameneh","year":"2019","journal-title":"Pharmacol. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature26157","article-title":"A new class of synthetic retinoid antibiotics effective against bacterial persisters","volume":"556","author":"Kim","year":"2018","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3946320231202349","DOI":"10.1177\/03946320231202349","article-title":"Drug repositioning of anti-microbial agent nifuratel to treat mast cell-mediated allergic responses","volume":"37","author":"Lee","year":"2023","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.drudis.2022.02.010","article-title":"Repurposing of the gold drug auranofin and a review of its derivatives as antibacterial therapeutics","volume":"27","author":"Liu","year":"2022","journal-title":"Drug Discov. Today"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02024-22","article-title":"Proton motive force inhibitors are detrimental to methicillin-resistant Staphylococcus aureus strains","volume":"10","author":"Mohiuddin","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.58147.sa2","article-title":"An adjunctive therapy administered with an antibiotic prevents enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen","volume":"9","author":"Morley","year":"2020","journal-title":"Elife"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7280","DOI":"10.1128\/AAC.01118-16","article-title":"Antibiofilm activity and synergistic inhibition of Staphylococcus aureus biofilms by bactericidal protein P128 in combination with antibiotics","volume":"60","author":"Nair","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1128\/AAC.00785-09","article-title":"Postantibiotic effect of ceftaroline against gram-positive organisms","volume":"53","author":"Pankuch","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.injury.2014.11.014","article-title":"Activity of bone cement loaded with daptomycin alone or in combination with gentamicin or PEG600 against Staphylococcus epidermidis biofilms","volume":"46","author":"Pe\u00f1alba Arias","year":"2015","journal-title":"Injury"},{"key":"B41","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s00018-022-04588-5","article-title":"L007\u20130069 kills Staphylococcus aureus in high resistant phenotypes","volume":"79","author":"Pengfei","year":"2022","journal-title":"Cell Mol. Life Sci."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70046","article-title":"Novel antibiotics against Staphylococcus aureus without detecta ble resistance by targeting proton motive force and FtsH","author":"Pengfei","year":"2025","journal-title":"MedComm"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007084","article-title":"Synergy between conventional antibiotics and anti-biofilm peptides in a murine, sub-cutaneous abscess model caused by recalcitrant ESKAPE pathogens","volume":"14","author":"Pletzer","year":"2018","journal-title":"PloS Pathog."},{"key":"B30","doi-asserted-by":"publisher","first-page":"12623","DOI":"10.1021\/acs.jmedchem.0c00826","article-title":"Nature-inspired (di)azine-bridged bisindole alkaloids with potent antibacterial in vitro and in vivo efficacy against methicillin-resistant Staphylococcus aureus","volume":"63","author":"Rehberg","year":"2020","journal-title":"J. Med. Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"lxae104","DOI":"10.1093\/jambio\/lxae104","article-title":"Development of novel indole-quinoline hybrid molecules targeting bacterial proton motive force","volume":"135","author":"Seo","year":"2024","journal-title":"J. Appl. Microbiol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.858606","article-title":"SPR741, double- or triple-combined with erythromycin and clarithromycin, combats drug-resistant Klebsiella pneumoniae, its biofilms, and persister cells","volume":"12","author":"She","year":"2022","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41586-018-0483-6","article-title":"Optimized arylomycins are a new class of Gram-negative antibiotics","volume":"561","author":"Smith","year":"2018","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202100749","article-title":"Plant natural flavonoids against multidrug resistant pathogens","volume":"8","author":"Song","year":"2021","journal-title":"Adv. Sci. (Weinh)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1128\/AAC.41.10.2173","article-title":"Postantibiotic effect of sanfetrinem compared with those of six other agents against 12 penicillin-susceptible and -resistant pneumococci","volume":"41","author":"Spangler","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ijantimicag.2019.03.024","article-title":"Repurposing disulfiram for treatment of Staphylococcus aureus infections","volume":"53","author":"Thakare","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ijantimicag.2018.11.008","article-title":"The antimetabolite 3-bromopyruvate selectively inhibits Staphylococcus aureus","volume":"53","author":"Visca","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7457","DOI":"10.1039\/c2ob25835h","article-title":"Small molecule control of bacterial biofilms","volume":"10","author":"Worthington","year":"2012","journal-title":"Org Biomol Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13568-023-01634-8","article-title":"Simeprevir restores the anti-Staphylococcus activity of polymyxins","volume":"13","author":"Wu","year":"2023","journal-title":"AMB Express"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2415952","DOI":"10.1080\/21505594.2024.2415952","article-title":"Bactericidal and anti-quorum sensing activity of repurposing drug Visomitin against Staphylococcus aureus","volume":"15","author":"Wu","year":"2024","journal-title":"Virulence"},{"key":"B23","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s00284-016-1081-1","article-title":"Crystal violet and XTT assays on Staphylococcus aureus biofilm quantification","volume":"73","author":"Xu","year":"2016","journal-title":"Curr. Microbiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/med.21946","article-title":"Bacterial proton motive force as an unprecedented target to control antimicrobial resistance","volume":"43","author":"Yang","year":"2023","journal-title":"Med. Res. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41522-017-0038-x","article-title":"Norgestimate inhibits staphylococcal biofilm formation and resensitizes methicillin-resistant Staphylococcus aureus to beta-lactam antibiotics","volume":"3","author":"Yoshii","year":"2017","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.618922","article-title":"Antibiofilm activity of small-molecule ZY-214\u20134 against Staphylococcus aureus","volume":"12","author":"Yu","year":"2021","journal-title":"Front. Microbiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"100117","DOI":"10.1016\/j.bioflm.2023.100117","article-title":"Berberine disrupts staphylococcal proton motive force to cause potent anti-staphylococcal effects in vitro","volume":"5","author":"Zhao","year":"2023","journal-title":"Biofilm"},{"key":"B17","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2147\/CMAR.S146173","article-title":"Nifuratel, a novel STAT3 inhibitor with potent activity against human gastric cancer cells","volume":"9","author":"Zheng","year":"2017","journal-title":"Cancer Manag Res."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00884-22","article-title":"Crizotinib shows antibacterial activity against gram-positive bacteria by reducing ATP production and targeting the CTP synthase PyrG","volume":"10","author":"Zheng","year":"2022","journal-title":"Microbiol. Spectr."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1738031\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:42:17Z","timestamp":1767940937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1738031\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":43,"alternative-id":["10.3389\/fcimb.2025.1738031"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1738031","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"article-number":"1738031"}}